CareFusion Launches Chemo Safety System to Improve Clinician And Patient Safety For Hazardous Drugs
First and Only Needle-Free Closed System Transfer Device for All Standard Vial Sizes
Dec 9, 2013
SAN DIEGO, Dec. 9, 2013 – CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today launched the Chemo Safety System, which is designed to improve clinician and patient safety when preparing, handling and administering hazardous pharmaceuticals.
The Chemo Safety System featuring the SmartSite VialShield™ is CareFusion’s FDA-cleared needle-free closed system transfer device (CSTD) available for all common vial sizes and is the only CSTD that achieves a closed system without the need for additional parts or pieces when used in conjunction with Alaris® IV sets. The new system helps protect health care personnel and patients from being exposed to hazardous drug vapor, spillage, spraying or surface contamination during drug reconstitution, transport and administration. The new system is designed to help optimize safety, simplify care and minimize costs.
Every day, pharmacists, nurses, physicians and other caregivers are exposed to hazardous drugs, such as those used for cancer therapy, antivirals, hormone agents and bioengineered drugs — all of which could threaten health care provider’s physical and reproductive health. Studies have shown a correlation between surface contamination and various health issues in exposed health care providers. Working with or near hazardous drugs in health care settings may put these providers at risk for skin rashes, infertility, miscarriage, birth defects and possibly leukemia and other cancers.
“We believe the new Chemo Safety System is a safe and simple way to prepare, transport and administer hazardous drugs,” said Vivek Jain, president of Procedural Solutions for CareFusion. “We have always been focused on patient safety, but this new system not only helps protect patients, it helps keep their caregivers safe as well.”
The Chemo Safety System combines existing technologies from CareFusion with new innovations to complete the system. The system includes Texium®, a needle-free closed male luer that attaches to SmartSite® needle-free connectors to form a closed system. Upon disconnect, the system is drip-free and leak-free to help prevent leaks and reduce surface contamination. Fluid can flow through the Texium connector only when connected to a SmartSite connector. The “passive” safety system technology of the Texium luer automatically closes and locks upon disconnection from the SmartSite needle-free connector, helping to prevent inadvertent syringe discharge.
More recent innovations include a full line of SmartSite vial adapters, which allow pharmacies to match their desired level of protection, clinical goals and budget within CareFusion’s portfolio of products. This includes the SmartSite VialShield, which is the first and only needle-free CSTD in the world compatible for 13mm, 20mm and 28mm vial sizes. The SmartSite VialShield is both mechanically and microbiologically closed, meaning it reduces surface contamination, traps vapors and prevents microbial ingress, which helps maintain sterility of the drug for up to seven days.
“The SmartSite VialShield is a game changer and is the centerpiece of Chemo Safety System,” said Jim Paloyan, vice president of Infusion Safety Disposables, Americas, for CareFusion. “This new line of vial adapters sets the standard of safety and simplicity and does so while streamlining workflow and reducing waste and costs for both pharmacy and nursing.”
The new product line also includes a comprehensive line of Texium syringes, where the connector is permanently affixed to the end of the syringe through a proprietary process to improve workflow and prevent accidental detachment that could lead to leakage. This helps increase safety while reducing waste and costs for both the pharmacy and nursing.
To address the concerns of nursing, CareFusion has created a full line of pre-assembled Texium IV sets to seamlessly integrate and provide automated protection for the administration of hazardous drugs in the patient care areas. A majority of hospitals across the U.S. already use Alaris IV sets, as they are standard with the Alaris® System line of infusion pumps from CareFusion. In effect, hospitals that use the Alaris System are already using a portion of the Chemo Safety System, which creates cost efficiencies previously not attainable with other closed systems. The Texium IV sets also include an integrated SmartSite Drug Transfer Port to help streamline workflow, reduce costs and increase safety in the pharmacy as well.
CareFusion made the announcement at the 48th Annual Midyear Clinical Meeting and Exhibition of the American Society of Health-Systems Pharmacists being held today through Thursday in the west concourse of the Orange County Convention Center in Orlando, Fla.
About CareFusion Corporation
CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops industry-leading technologies including Alaris® infusion pumps and IV sets, MaxPlus® and MaxZero™ IV connectors and sets, Pyxis® automated dispensing and patient identification systems, AVEA®, LTV® series and AirLife® ventilation and respiratory products, ChloraPrep® products, MedMined® services for data mining surveillance, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs approximately 15,000 people across its global operations. More information may be found at www.carefusion.com.
 VialShield is available for 13mm, 20mm and 28mm vial sizes.
 National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC). Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Healthcare Settings. DHHS (NIOSH) publication number 2004-165, September 2004.
For further information: Media: Troy Kirkpatrick - (858) 617-2361 - firstname.lastname@example.org Investors: Jim Mazzola - (858) 617-1203 - email@example.com